Pharmacosmos Holding AS v. Daiichi Sankyo Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Pharmacosmos Holding A/S (Denmark), Pharmacosmos A/S (Denmark), and Pharmacosmos Therapeutics Inc. (Delaware)
  • Defendant: Daiichi Sankyo, Inc. (New Jersey) and American Regent, Inc. (New York)
  • Plaintiff's Counsel: Chiesa Shahinian & Giantomasi PC
• Case Identification: 1:25-cv-15857, D.N.J., 09/22/2025
• Venue Allegations: Venue is alleged to be proper in the District of New Jersey because Defendant Daiichi Sankyo is incorporated and maintains its principal place of business in the state. Venue is alleged to be proper as to Defendant American Regent based on its commission of infringing acts within the district and its alleged status as an agent and alter ego of Daiichi Sankyo.
• Core Dispute: Plaintiff alleges that Defendants' intravenous iron product, Injectafer®, infringes four U.S. patents related to methods of treating iron deficiency with ferric carboxymaltose while mitigating the risk of side effects, particularly hypophosphatemia.
• Technical Context: The technology concerns therapeutic methods for administering intravenous iron to treat iron deficiency anemia, a prevalent condition, while managing specific biochemical side effects associated with the treatment.
• Key Procedural History: The complaint alleges that prior to the lawsuit, the parties engaged in discussions regarding the patent applications that issued as the patents-in-suit, placing Defendants on notice of their potential infringement. It is also alleged that following the patents' priority date, regulatory agencies required Defendants to revise the accused product's label to include warnings and monitoring instructions related to hypophosphatemia, a central aspect of the patented technology.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,020,369 - Treating Iron Deficiency with Ferric Carboxymaltose (Issued June 1, 2021)

The Invention Explained

• Problem Addressed: The patent addresses the problem of side effects associated with intravenous (IV) administration of ferric carboxymaltose (FCM) for iron deficiency '369 Patent, col. 1:13-21 Specifically, it identifies that FCM can induce hypophosphatemia (low serum phosphate), a side effect mediated by the hormone FGF23 '369 Patent, col. 2:14-20 The inventors assert a discovery that repeated dosing of FCM leads to a "surprising" and "self-amplifying effect," causing a two- to three-fold higher increase in FGF23 after a second dose, exacerbating the side effects Compl. ¶48 '369 Patent, col. 3:12-19
• The Patented Solution: The invention claims methods for treating iron deficiency with a repeat-dosing regimen of FCM administered only to a select subgroup of patients who have a "reduced risk for FGF23-mediated side effects" '369 Patent, abstract '369 Patent, col. 3:52-54 This reduced risk is determined by screening for specific patient characteristics, such as having normal blood or urine parameters (e.g., normal serum phosphate), the absence of certain exclusion criteria (e.g., bariatric surgery or obesity), or having normal respiratory capacity '369 Patent, col. 4:30-51 By pre-selecting a patient population less susceptible to these side effects, the method aims to provide effective treatment while mitigating the risks of repeat dosing.
• Technical Importance: The invention provided a method to manage previously underappreciated severe side effects of a common IV iron treatment, particularly the auto-synergistic negative effects of repeat dosing Compl. ¶¶38-39

Key Claims at a Glance

The complaint asserts independent claim 1 and dependent claims 2-5 and 16 Compl. ¶67

• Independent Claim 1:
  • A method of treating iron deficiency comprising administering a dose followed by a further dose of ferric carboxymaltose.
  • The dosing regimen is specified as either two 750 mg doses or a 1000 mg dose followed by a 500-1000 mg dose.
  • The method is limited to a "subject [who] has a reduced risk for FGF23-mediated side effects."
  • This "reduced risk" is defined by the subject meeting one of four criteria: (I) having certain normal blood/urine parameters (e.g., serum phosphate >2.5 mg/dL); (II) having certain normal blood parameters related to bone turnover; (III) lacking certain exclusion criteria (e.g., obesity); or (IV) having normal respiratory capacity.

U.S. Patent No. 11,806,329 - Treating Iron Deficiency with Ferric Carboxymaltose (Issued November 7, 2023)

The Invention Explained

• Problem Addressed: Similar to the '369 patent, this patent addresses the "self-amplifying effect" of repeat dosing of FCM, which leads to a two- to three-fold higher increase in FGF23 after a second dose and can cause clinically significant hypophosphatemia '329 Patent, col. 3:15-31 Compl. ¶53
• The Patented Solution: The invention provides methods for treating iron deficiency with repeated doses of FCM, but limits the treatment to subjects who have a "reduced risk for hypophosphatemia," which is specifically defined as the subject having a "normal serum phosphate level" '329 Patent, abstract '329 Patent, col. 14:19-24 A separate set of claims is directed to methods of monitoring a patient's serum phosphate level after an initial dose of FCM and determining the patient is eligible for a further dose only "if the serum phosphate level is normal" '329 Patent, claim 16
• Technical Importance: This invention identified a specific, readily measurable biomarker-normal serum phosphate level-as the key criterion for safely administering repeat doses of FCM, providing a direct clinical tool to mitigate previously underappreciated risks Compl. ¶53

Key Claims at a Glance

The complaint asserts independent claims 1 and 16, as well as dependent claims 2-15, 17-25, and 33-34 Compl. ¶101 Compl. ¶¶116-117

• Independent Claim 1:
  • A method of treating iron deficiency in a human subject comprising administering a dose followed by a further dose of ferric carboxymaltose.
  • The dosing regimen is specified as either two 750 mg doses or a 1000 mg dose followed by a 500-1000 mg dose.
  • The method is limited to a subject who "has a reduced risk for hypophosphatemia."
  • This "reduced risk" is further defined as the subject having "a normal serum phosphate level."
• Independent Claim 16:
  • A method of monitoring serum phosphate level in a human subject who has been administered a dose of ferric carboxymaltose.
  • The method comprises determining the serum phosphate level in a biological sample from the subject.
  • The subject is determined to be "eligible for being administered a further dose of ferric carboxymaltose if the serum phosphate level is normal."

U.S. Patent No. 12,295,934 - Treating Iron Deficiency with Ferric Carboxymaltose (Issued May 13, 2025)

• Technology Synopsis: The patent claims methods to reduce the severity of side effects from repeated FCM treatment for iron deficiency. The methods require measuring a subject's serum phosphate levels before administering a further dose, and if hypophosphatemia is detected, treating that condition before proceeding with the additional FCM dose Compl. ¶56
• Asserted Claims: The complaint discusses independent claims 1 and 31 and alleges infringement of claims 1-60 Compl. ¶¶133-135 Compl. ¶145
• Accused Features: The accused features are the instructions on the 2025 Injectafer® Label that direct healthcare providers to "[c]heck serum phosphate levels prior to a repeat course of treatment" and to "[t]reat hypophosphatemia as medically indicated" Compl. ¶137 Compl. ¶141

U.S. Patent No. 12,303,486 - Treating Iron Deficiency with Ferric Carboxymaltose (Issued May 20, 2025)

• Technology Synopsis: This patent claims methods for reducing the risk of symptomatic hypophosphatemia associated with repeated FCM treatment. The claimed methods are similar to those in the '934 patent, requiring evaluation of serum phosphate levels and correction of any hypophosphatemia prior to administering a further dose of FCM Compl. ¶61
• Asserted Claims: The complaint discusses independent claim 1 and alleges infringement of claims 1-29 Compl. ¶¶170-172
• Accused Features: The accused features are the instructions on the 2025 Injectafer® Label directing providers to monitor and treat hypophosphatemia, which allegedly reduces the risk of symptomatic outcomes Compl. ¶174 Compl. ¶178

III. The Accused Instrumentality

Product Identification

The accused product is Injectafer® (ferric carboxymaltose injection), an intravenous drug product Compl. ¶1 No probative visual evidence provided in complaint.

Functionality and Market Context

• Injectafer® is an iron carbohydrate complex indicated for the intravenous treatment of iron deficiency anemia in adults and pediatric patients who have an intolerance or unsatisfactory response to oral iron, and in adult patients with non-dialysis dependent chronic kidney disease Compl. ¶10 It is also indicated for treating iron deficiency in adult patients with heart failure Compl. ¶10
• The product is administered in dosages including 750 mg intravenously in two doses, or as a single-dose course up to 1000 mg Compl. ¶10 Compl. ¶72 The product's labeling, as described in the complaint, instructs that "Injectafer treatment may be repeated if iron deficiency anemia reoccurs" Compl. ¶71 The complaint alleges that various versions of the product label include instructions to monitor patients at risk for low serum phosphate and to treat hypophosphatemia Compl. ¶¶41-43 Compl. ¶73
• The complaint alleges that Injectafer® is a direct competitor to Plaintiff's Monoferric® product and that over 3 million U.S. patients have been treated with it Compl. ¶6 Compl. ¶16 It is allegedly manufactured under license by American Regent and marketed by Daiichi Sankyo Compl. ¶9

IV. Analysis of Infringement Allegations

U.S. Patent No. 11,020,369 Infringement Allegations

U.S. Patent No. 11,806,329 Infringement Allegations

• Identified Points of Contention:
  • Scope Questions: The infringement allegations for the '369 Patent center on the argument that by instructing physicians to identify and monitor patients "at risk" for a side effect, the label necessarily instructs them to treat the complementary group of patients who have a "reduced risk" as defined by the patent. A central question may be whether following the label's general risk mitigation guidance equates to the specific, multi-part patient selection criteria recited in claim 1.
  • Technical Questions: A key factual question is whether a healthcare provider, following the standard of care and the Injectafer® label, would necessarily perform all the steps of the claimed methods. For example, does an instruction to "[c]heck serum phosphate levels" Compl. ¶82 and treat if low, necessarily mean that a provider is practicing a method of selecting a patient with a "normal serum phosphate level" for the purpose of reducing FGF23-mediated side effects, as the patents claim? The defense may argue that such monitoring is a general safety precaution, not the specific selection method claimed.

V. Key Claim Terms for Construction

• The Term: "a subject [who] has a reduced risk for FGF23-mediated side effects" / "a reduced risk for hypophosphatemia"

  • Context and Importance: These phrases are the core of the asserted claims, as they define the specific patient population to which the patented methods apply. The outcome of the case may depend on whether the patients treated according to the Injectafer® label are construed as falling within this population.
  • Intrinsic Evidence for a Broader Interpretation: The patent specifications describe the overall goal of mitigating side effects, which could support an argument that any patient not actively exhibiting risk factors has a "reduced risk" Compl. ¶47 '369 Patent, col. 3:45-51
  • Intrinsic Evidence for a Narrower Interpretation: The claims themselves appear to act as their own dictionary. Claim 1 of the '369 Patent follows the "reduced risk" phrase with "wherein the subject having a reduced risk...:" and then lists four specific, alternative categories of criteria (e.g., specific blood parameters, absence of exclusion criteria) '369 Patent, claim 1 Claim 1 of the '329 Patent explicitly defines the subject with a "reduced risk" as one who "has a normal serum phosphate level" '329 Patent, claim 1 This language may support a narrow construction where the term is limited to the specific definitions provided in the claims.

• The Term: "normal serum phosphate level"

  • Context and Importance: This term is the specific biomarker required by claim 1 of the '329 Patent and is one of the optional criteria in claim 1 of the '369 Patent. Its precise numerical definition will be critical for determining infringement.
  • Intrinsic Evidence for a Broader Interpretation: The term "normal" could be argued to refer to a standard clinical range that may vary by laboratory or clinical context, rather than a single fixed number. The specification discusses the concept generally before providing a specific value '329 Patent, col. 2:20-22
  • Intrinsic Evidence for a Narrower Interpretation: Claim 1 of the '369 Patent specifies "normal serum phosphate level, in particular >2.5 mg/dL" '369 Patent, claim 1 The shared specification for the patents also states that hypophosphatemia is characterized by "too low serum phosphate" and provides a table where levels below 2.5 mg/dL are categorized as Grade 1 adverse events, suggesting that a level at or above this threshold is "normal" for the purposes of the invention '329 Patent, col. 7:54-8:5

VI. Other Allegations

• Indirect Infringement: The complaint exclusively alleges induced infringement under 35 U.S.C. § 271(b) Compl. ¶64 Compl. ¶95 Compl. ¶127 Compl. ¶164 The theory is that Defendants actively encourage and direct healthcare providers to perform the patented methods by distributing the Injectafer® product with labels and marketing materials that instruct on repeated dosing, monitoring for hypophosphatemia risk, and treating the condition before administering further doses Compl. ¶86 Compl. ¶118
• Willful Infringement: Willfulness is alleged for all four patents. The complaint asserts that Defendants had actual, pre-suit knowledge of the patents and their parent applications based on "ongoing discussions" that took place between the parties from at least March 2021 to January 2022 Compl. ¶66 Compl. ¶97 During these discussions, Pharmacosmos allegedly notified Defendants that sales of Injectafer® would infringe, and Defendants allegedly sought a covenant-not-to-sue Compl. ¶66 Compl. ¶97 The complaint alleges that Defendants' continued marketing and sale of Injectafer® with the accused instructions, despite this alleged knowledge, constitutes willful infringement Compl. ¶¶89-91

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of instructional scope: do the Injectafer® label's directions to monitor for "risk of low serum phosphate" and "treat hypophosphatemia as medically indicated" constitute affirmative instructions to perform the specific patient-selection and multi-step treatment regimens recited in the patent claims, or are they general safety warnings that do not directly map onto the patented methods?
• A key question of claim construction will be the definition of a patient with a "reduced risk." The court will need to decide if this term is limited to the specific criteria laid out in the claims (e.g., normal phosphate levels, absence of obesity) or if it can be interpreted more broadly, and whether following the product label necessarily results in the selection of such a patient.
• An evidentiary focus for willfulness will be the pre-suit communications between the parties. The case may turn on what specific notice was provided regarding the scope of the pending and issued claims, and whether Defendants' subsequent actions in revising and distributing the Injectafer® label demonstrate a deliberate disregard of known patent rights.